According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.
Four gurus have positions in Corcept Therapeutics Inc. (CORT, Financial) with a total weight of 0.13% on their portfolios.
The biotechnology company has a market cap of $1.83 billion. Its revenue grew 64% over the past 12 months and its EPS increased 625%.
The stock is trading with a price-earnings (P/E) ratio of 55.42. The current stock price of $16.07 is 21.43% below its 52-week high and 143.58% above its 52-week low. Over the past decade, it has returned a gain of 458%.
In the third quarter,Ă‚ Joel Greenblatt (Trades, Portfolio) added 11.39% to his position.
Four gurus are invested in Acceleron Pharma Inc. (XLRN, Financial) with a combined portfolio weight of 0.17%.
The biotechnology company has a market cap of $1.59 billion. Its revenue has declined 55% over the past five years.
The current stock price of $35.06 is 12.60% below its 52-week high and 52.88% above its 52-week low. Over the past decade, it has returned a gain of 75%.
In the third quarter,Ă‚ Leon Cooperman (Trades, Portfolio) established a position in the company and Ron Baron (Trades, Portfolio) increased his holding by 0.32%.
Three gurus have positions in Enzymotec Ltd. (ENZY, Financial).
The manufacturer of nutritional ingredients and medical foods has a market cap of $277.15 billion. The current stock price of $11.83 is 4.45% below its 52-week high and 11.85% above its 52-week low. Over the past decade, it has returned a loss of 35%.
In the third quarter,Ă‚ John Paulson (Trades, Portfolio) reduced his holding by 50%.
Four gurus are shareholders of Sangamo Therapeutics Inc. (SGMO, Financial).
The clinical-stage biotechnology company has a market cap of $1.37 billion. The current stock price of $16.25 is 10.05% below its 52-week high and 46.46% above its 52-week low. Over the past decade, it has returned a gain of 16%.
Over the past 10 years, Sangamo Therapeutics’ revenue grew 4.80% and its EPS increased 1.60%.
Greenblatt bought 26,695 shares of the company during the third quarter.
Nine gurus are invested in Biomarin Pharmaceutical Inc. (BMRN, Financial).
The biopharmaceutical company has a market cap of $14.23 billion. The current stock price of $80.75 is 19.41% below its 52-week high and 1.12% above its 52-week low. Over the past decade, it has returned a gain of 186%.
Biomarin Pharmaceutical’s revenue grew 17.70% over the past decade.
George Soros (Trades, Portfolio) exited his holding in the third quarter. Greenblatt established a position.
Disclosure: I do not own any shares of any stocks mentioned in this article.
